Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium, quantity: 10.396 mg - tablet, film coated - excipient ingredients: lactose; colloidal anhydrous silica; maize starch; hypromellose; sodium stearylfumarate; microcrystalline cellulose; silicon dioxide; purified talc; mannitol; macrogol 6000; titanium dioxide; iron oxide yellow; iron oxide red - rosuvastatin sandoz should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin sandoz is indicated for prevention of major cardiovascular events in men greater than equal to 50 years old and women greater than equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,rosuvastatin sandoz is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin sandoz is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rosuvastatin calcium, quantity: 5.198 mg - tablet, film coated - excipient ingredients: hypromellose; maize starch; sodium stearylfumarate; colloidal anhydrous silica; silicon dioxide; mannitol; lactose; microcrystalline cellulose; purified talc; macrogol 6000; titanium dioxide; iron oxide yellow; iron oxide red - rosuvastatin sandoz should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events,rosuvastatin sandoz is indicated for prevention of major cardiovascular events in men greater than equal to 50 years old and women greater than equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease).,rosuvastatin sandoz is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia,rosuvastatin sandoz is indicated for the treatment of hypercholesterolaemia (excluding heterozygous familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin sandoz, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Bandaríkin - enska - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are

Bandaríkin - enska - NLM (National Library of Medicine)

viona pharmaceuticals inc - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - - clopidogrel tablet is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablet is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin.  in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablet is indicated to reduce the rate of mi and stroke. clopidogrel bisulfate is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracran

Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clopidogrel hydrogen sulfate, quantity: 97.88 mg; aspirin, quantity: 75 mg - tablet, film coated - excipient ingredients: maize starch; methylcellulose; hyprolose; zinc stearate; lactose; iron oxide yellow; crospovidone; microcrystalline cellulose; macrogol 8000; colloidal anhydrous silica; hypromellose; titanium dioxide - clopidogrel/aspirin is a fixed dose combination product. clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products:,? unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,? st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Malta - enska - Medicines Authority

billev pharma aps fuglebækgaard, elmegårdsvej 1a, tørslev, 3630 jægerspris, denmark - clopidogrel, acetylsalicylic acid - film-coated tablet - clopidogrel 75 mg acetylsalicylic acid 75 mg - antithrombotic agents

Malta - enska - Medicines Authority

billev pharma aps fuglebækgaard, elmegårdsvej 1a, tørslev, 3630 jægerspris, denmark - clopidogrel, acetylsalicylic acid - film-coated tablet - clopidogrel 75 mg acetylsalicylic acid 100 mg - antithrombotic agents

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: lactose; glyceryl behenate; crospovidone; purified talc; microcrystalline cellulose; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: clopidogrel is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Bandaríkin - enska - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - for patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel tablets usp have been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (mi), or stroke as well as the rate of a combined endpoint of cardiovascular death, mi, stroke, or refractory ischemia. - for patients with st-elevation myocardial infarction (stemi), clopidogrel tablets usp have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. the benefit for patients who undergo primary percutaneous coronary intervention is unknown. the optimal duration of clopidogrel tablet usp therapy in acs is unknown. for patients with a history of recent myocardial infarction (mi), recent stroke, or established peripheral arterial disease, clopidogrel tablets usp ha